1329 related articles for article (PubMed ID: 16709592)
1. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice.
Khan MA; Nasti TH; Owais M
J Antimicrob Chemother; 2005 Oct; 56(4):726-31. PubMed ID: 16126780
[TBL] [Abstract][Full Text] [Related]
3. Safety, efficacy and pharmacokinetics of tuftsin-loaded nystatin liposomes in murine model.
Khan MA; Faisal SM; Mohammad O
J Drug Target; 2006 May; 14(4):233-41. PubMed ID: 16777682
[TBL] [Abstract][Full Text] [Related]
4. Tuftsin-mediated immunoprophylaxis against an isolate of Aspergillus fumigatus shows less in vivo susceptibility to amphotericin B.
Khan MA; Ahmad N; Moin S; Mannan A; Wajahul H; Pasha ST; Khan A; Owais M
FEMS Immunol Med Microbiol; 2005 Jun; 44(3):269-76. PubMed ID: 15907448
[TBL] [Abstract][Full Text] [Related]
5. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
Chakraborty KK; Naik SR
J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
[TBL] [Abstract][Full Text] [Related]
7. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
9. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP
J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589
[TBL] [Abstract][Full Text] [Related]
10. Co-administration of immunomodulator tuftsin and liposomised nystatin can combat less susceptible Candida albicans infection in temporarily neutropenic mice.
Khan MA; Nasti TH; Saima K; Mallick AI; Firoz A; Wajahul H; Ahmad N; Mohammad O
FEMS Immunol Med Microbiol; 2004 Jul; 41(3):249-58. PubMed ID: 15196575
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulator tuftsin increases the susceptibility of Cryptococcus neoformans to liposomal amphotericin B in immunocompetent BALB/c mice.
Khan MA; Owais M
J Drug Target; 2005 Aug; 13(7):423-9. PubMed ID: 16308211
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic use of liposomized tuftsin enhances the susceptibility of Candida albicans to fluconazole in leukopenic mice.
Khan MA; Khan A; Owais M
FEMS Immunol Med Microbiol; 2006 Feb; 46(1):63-9. PubMed ID: 16420598
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis.
Amaral AC; Bocca AL; Ribeiro AM; Nunes J; Peixoto DL; Simioni AR; Primo FL; Lacava ZG; Bentes R; Titze-de-Almeida R; Tedesco AC; Morais PC; Felipe MS
J Antimicrob Chemother; 2009 Mar; 63(3):526-33. PubMed ID: 19151037
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulator tuftsin augments anti-fungal activity of amphotericin B against experimental murine candidiasis.
Masood AK; Faisal SM; Haque W; Owais M
J Drug Target; 2002 May; 10(3):185-92. PubMed ID: 12075819
[TBL] [Abstract][Full Text] [Related]
15. Use of tuftsin bearing nystatin liposomes against an isolate of Candida albicans showing less in vivo susceptibility to amphotericin B.
Khan MA; Syed FM; Nasti HT; Saima Dagger K; Haq W; Shehbaz A; Owais M
J Drug Target; 2003 Feb; 11(2):93-9. PubMed ID: 12881195
[TBL] [Abstract][Full Text] [Related]
16. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis.
Kretschmar M; Nichterlein T; Hannak D; Hof H
Arzneimittelforschung; 1996 Jul; 46(7):711-5. PubMed ID: 8842344
[TBL] [Abstract][Full Text] [Related]
17. Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B.
Ahmad I; Sarkar AK; Bachhawat BK
Indian J Biochem Biophys; 1989 Dec; 26(6):351-6. PubMed ID: 2698855
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a new formulation of amphotericin B in murine disseminated infections by Candida glabrata or Candida tropicalis.
Mariné M; Espada R; Torrado J; Pastor FJ; Guarro J
Int J Antimicrob Agents; 2009 Dec; 34(6):566-9. PubMed ID: 19733036
[TBL] [Abstract][Full Text] [Related]
19. Amphotericin-B-loaded polymersomes formulation (PAMBO) based on (PEG)₃-PLA copolymers: an in vivo evaluation in a murine model.
Jain JP; Jatana M; Chakrabarti A; Kumar N
Mol Pharm; 2011 Feb; 8(1):204-12. PubMed ID: 21138276
[TBL] [Abstract][Full Text] [Related]
20. Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes).
Kretschmar M; Amselem S; Zawoznik E; Mosbach K; Dietz A; Hof H; Nichterlein T
Mycoses; 2001; 44(7-8):281-6. PubMed ID: 11714063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
